Oxford Square Capital (NASDAQ:OXSQ – Get Free Report) and Hyperion DeFi (NASDAQ:HYPD – Get Free Report) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Analyst Recommendations
This is a summary of current recommendations and price targets for Oxford Square Capital and Hyperion DeFi, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oxford Square Capital | 1 | 0 | 0 | 0 | 1.00 |
| Hyperion DeFi | 1 | 1 | 2 | 0 | 2.25 |
Hyperion DeFi has a consensus price target of $7.20, indicating a potential upside of 154.42%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, analysts clearly believe Hyperion DeFi is more favorable than Oxford Square Capital.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oxford Square Capital | $40.34 million | 3.98 | -$18.73 million | ($0.45) | -3.31 |
| Hyperion DeFi | $810,000.00 | 52.97 | -$45.31 million | ($9.95) | -0.28 |
Oxford Square Capital has higher revenue and earnings than Hyperion DeFi. Oxford Square Capital is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Oxford Square Capital has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.
Institutional & Insider Ownership
6.4% of Oxford Square Capital shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 6.5% of Oxford Square Capital shares are held by insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Oxford Square Capital and Hyperion DeFi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oxford Square Capital | -93.65% | 14.23% | 6.76% |
| Hyperion DeFi | N/A | -91.59% | -73.08% |
Summary
Hyperion DeFi beats Oxford Square Capital on 9 of the 14 factors compared between the two stocks.
About Oxford Square Capital
Oxford Square Capital Corp. is a business development company, operates as a closed-end, non-diversified management investment company. It is a private equity and mezzanine firm. The firm invests in both public and private companies. It invests in secured and unsecured senior debt, subordinated debt, junior subordinated debt, preferred stock, common stock and syndicated bank loans. The firm primarily invests in debt and/or equity securities of technology-related companies that operate in the computer software, Internet, information technology infrastructure and services, media, telecommunications and telecommunications equipment, semiconductors, hardware, technology-enabled services, semiconductor capital equipment, medical device technology, diversified technology, and networking systems sectors. It concentrates its investments in companies having annual revenues of less than $200 million and a market capitalization or enterprise value of less than $300 million. The firm invests between $5 million and $30 million per transaction. It seeks to exit its investments within 7 years. It serves as the investment adviser to TICC. Oxford Square Capital Corp., formerly known as TICC Capital Corp., was founded in 2003 and is headquartered in Greenwich, Connecticut.
About Hyperion DeFi
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Receive News & Ratings for Oxford Square Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Square Capital and related companies with MarketBeat.com's FREE daily email newsletter.
